Literature DB >> 19272012

Innate immune recognition of viruses and viral vectors.

Xiaopei Huang1, Yiping Yang.   

Abstract

Recombinant viral vectors such as adenovirus and adenovirus-associated virus have been used widely as vehicles for gene therapy applications because of the high efficiency with which they transfer genes into a wide spectrum of cells in vivo. However, enthusiasm for the use of viral vectors in gene therapy has been tempered by significant problems of attendant host cellular and humoral immune responses that limit their safety and efficacy in vivo. Advances in immunology have suggested a crucial role for the innate immune system in the induction of immune responses to viruses. Thus, a better understanding of the mechanisms by which the host's innate immune system recognizes viruses and viral vectors will help in the design of effective strategies to improve the outcome of viral vector-mediated gene therapy. In this review we first discuss our current understanding of innate immune recognition of viruses in general, and then focus on the innate immune responses to viral vectors for gene therapy.

Mesh:

Substances:

Year:  2009        PMID: 19272012      PMCID: PMC2858295          DOI: 10.1089/hum.2008.141

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  109 in total

Review 1.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

Review 2.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

3.  Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration.

Authors:  M A Kay; A X Holterman; L Meuse; A Gown; H D Ochs; P S Linsley; C B Wilson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

4.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

5.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways.

Authors:  Hubertus Hochrein; Beatrix Schlatter; Meredith O'Keeffe; Cornelia Wagner; Frank Schmitz; Matthias Schiemann; Stefan Bauer; Mark Suter; Hermann Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-22       Impact factor: 11.205

7.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.

Authors:  R W Herzog; E Y Yang; L B Couto; J N Hagstrom; D Elwell; P A Fields; M Burton; D A Bellinger; M S Read; K M Brinkhous; G M Podsakoff; T C Nichols; G J Kurtzman; K A High
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

8.  TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function.

Authors:  Anne Krug; Anthony R French; Winfried Barchet; Jens A A Fischer; Andrzej Dzionek; Jeanette T Pingel; Michael M Orihuela; Shizuo Akira; Wayne M Yokoyama; Marco Colonna
Journal:  Immunity       Date:  2004-07       Impact factor: 31.745

9.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.

Authors:  T R Flotte; S A Afione; C Conrad; S A McGrath; R Solow; H Oka; P L Zeitlin; W B Guggino; B J Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

10.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

View more
  39 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

2.  NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

3.  Vimentin knockdown decreases corneal opacity.

Authors:  Subrata K Das; Isha Gupta; Yang Kyung Cho; Xiaohui Zhang; Hironori Uehara; Santosh Kumar Muddana; Ashlie A Bernhisel; Bonnie Archer; Balamurali K Ambati
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

4.  DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice.

Authors:  Tomoya Terashima; Kazuhiro Oka; Angelika B Kritz; Hideto Kojima; Andrew H Baker; Lawrence Chan
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

5.  TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells.

Authors:  Graeme E Glass; James K Chan; Andrew Freidin; Marc Feldmann; Nicole J Horwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-05       Impact factor: 11.205

6.  Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

Review 7.  Progress and prospects: immune responses to viral vectors.

Authors:  S Nayak; R W Herzog
Journal:  Gene Ther       Date:  2009-11-12       Impact factor: 5.250

8.  Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.

Authors:  Laura Ahtiainen; Cristina Mirantes; Tiina Jahkola; Sophie Escutenaire; Iulia Diaconu; Pamela Osterlund; Anna Kanerva; Vincenzo Cerullo; Akseli Hemminki
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

9.  Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Authors:  Monica M Sauter; Joshua J L Gauger; Curtis R Brandt
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

10.  Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung.

Authors:  Maria P Limberis; Christie L Bell; Jack Heath; James M Wilson
Journal:  Mol Ther       Date:  2009-09-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.